From discovery to diagnostics: iCura’s cutting-edge spatial biology platforms accelerate research and development, paving the way for personalized medicine and targeted therapies.
Akoya Bioscience’s PhenoImager HT (Ver. 2.0)
Automated high-throughput multiplex immunofluorescence (mIF/IHC) platform for precise biomarker analysis.
Combined with Leica BOND RX, the PhenoImager HT with the most recent software package canprovide high-throughput staining and scanning, up to 80 slides staining and 200 slides scanning in 24 hours.
Brightfield and fluorescence capabilities. Integrated InForm 3.0 image analysis software.
mIF Panels
1) Akoya MOTiF Melanoma kit: S100 /Sox10, CD8, CD68, FoxP3, PD -l, PD -L1
2) TME panel: CD25, CD8, FoxP3, PD -L1, Granzyme B
3) Hodgkin’s Lymphoma, including CD30, CD15, Pax -5, CD20, and MUM – 1
4) Glioblastoma microenvironment panel: BRAF600E, Sox2, TMEM119, CD68, CD163, pERK
5) T cell and Macrophage for TME: CD4, CD8, Ki -67, Granzyme B, iNOS, CD68, CD163, PanCK (AE1 /AE3)
6) Dendritic Cells and Myeloid Derived Suppressor Cells: CD11c, CD11b, CD123, HLA -DR, CD14, CD15, PanCK (AE1 /AE3 )
7) Custom panels are designed upon client’s request
Phenocode Panels
1) Immuno-Contexture Human Protein Panel: CD8, CD68, PD-L1, FoxP3, PanCK (Determine whether tumors are hot or cold)
2) Immune Profile Human Protein Panel: CD8, CD3e, CD68, CD20, PanCK (Identify immune cells in the TME)
3) Activated TIL Status Human Protein Panel: CD8, CD3e, Ki67, Granzyme B, PanCK (Characterize the activation status of TILs)
4) M1/M2 Polarized Human Protein Panel: CD8, CD68, CD163, PD-1, PD-L1 (Identify TAMs in the TME)
5) T Cell Status Human Protein Panel: CD8, CD4, CD20, FoxP3, PD-1 (Characterize the exhaustion status of T cells)
Leica BOND RX
Offers automated staining for IHC, IF, and ISH, with flexibility of customized protocols, used for RUO and LDT purposes.
Processes 30 to 60 slides per instrument in 24 hours depending on protocol.
NextSeq 2000
High-throughput sequencing: Generates large amounts of data in a short time.
Flexible: Handles various applications like RNA-seq, whole exome sequencing, targeted sequencing.
Scalable: Accommodates different run sizes.
Qiagen Qiacuity ndPCR
Digital PCR based on Nano-Plate technology. A highly sensitive quantitative assay with an efficient workflow. Provides absolute quantification (no standard curve required) and multiplexing capabilities.
A powerful tool for detecting extremely low levels of nucleic acid (e.g., cfDNA) and supporting cell and gene therapy development processes.
At iCura, we’re committed to providing best in class services for translational and clinical research. From our CLIA / CAP approved laboratory in Philadelphia, we work with research teams on the bleeding edge of oncology, immuno-oncology, and cell and gene therapies.
Our comprehensive molecular profiles help scientists understand how complex biological systems interact with immaculate precision. We don’t just provide data, we provide expert guidance based to inform translational and clinical decisions.
We have decades of combined experience in biomarker research, particularly in cancer and rare diseases. Our spatial phenotyping platform can help you identify new targets, understand how your drugs work, the immune landscape in tumors, and predict which patients will respond to selected treatments.
For cell and gene therapy drugs, we offer industry leading nano-plate based PCR (ndPCR) assays to address some of the most pressing challenges in the field such as identifying rare mutations, quantifying CNVs and residual host cell DNA to name a few.
Lastly, our expert teams can support your clinical study with comprehensive solutions for sample management, analysis, and logistics.
Reach out to us today to see how we can partner with you and help bring your innovative therapies to the clinic and make precision medicine a reality.